cut and paste from old SEC filings. just hunting and pecking, not exhaustive.....
ACADIA Pharmaceuticals. On December 18, 2000, ArQule and ACADIA Pharmaceuticals entered into a drug discovery collaboration. Under the agreement, ACADIA combined its functional genomics platform with ArQule's Parallel Track Drug Discovery Program to discover novel small-molecule drug candidates directed at individual G-protein coupled receptor (GPCR) targets. The companies shared intellectual property resulting from the collaboration. Under the agreement, the companies will share any revenues resulting from the commercialization of joint drug discovery programs. In addition to these joint drug discovery programs, each company will receive exclusive rights to certain compounds that the companies have decided not to develop in a joint drug discovery program, subject to a royalty payment to the other party. In July 2002, we decided to cease our efforts on this collaboration in order to focus on our internal drug discovery programs.
(snip)
Since the probability of successful identification of small molecule drug
candidates increases as more compounds are evaluated against a greater number of
screens, Genzyme actively seeks collaborations to complement its internal
efforts. GMO has a collaboration with the NCI under which the NCI is screening
Genzyme's small molecule compound libraries against a cancer screen
incorporating 60 different tumor cell lines. In addition, Genzyme has entered
into agreements with Acadia Pharmaceuticals Inc. ("Acadia") and NOVALON
Pharmaceutical Corporation ("NOVALON") under which the Genzyme compound
libraries will be screened against Acadia's cell-based assays and NOVALON's
proprietary BioKey(TM) assays.
(snip)
In September 1997, the Company [Allergan] entered into an
exclusive collaboration agreement with ACADIA Pharmaceuticals Inc. (formerly
Receptor Technologies) to identify receptor-selective compounds with respect to
certain targets, develop receptor arrays and probes specific for G-protein
coupled and other receptors and facilitate the establishment of drug discovery
programs.
(snip)
first S-1 was filed 12/21/2000. Should make an interesting read. Appears to have been in the portfolio of several funds that are private/public?? Chomping at the bit to move the shares. |
